Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2007-08-14
2007-08-14
Wax, Robert A. (Department: 1656)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C514S002600, C424S185100
Reexamination Certificate
active
11066697
ABSTRACT:
A secretin or secretin derivative protected against peptidase activity. The secretin or derivative comprises a peptidic sequence and a reactive group selected from the group consisting of succinimidyl and maleimido groups capable of reacting with an amino group, hydroxyl group or thiol group on a blood component to form a stable covalent bond. The reactive group is attached at a position along the peptidic sequence that provides, when conjugated to a blood component, a higher stability against peptidase degradation than the unconjugated secretin or derivative, and therefore an increased maintenance of the therapeutic activity compared to the unconjugated secretin or derivative. Such a compound is thus effective to provide a source of secretin having a high stability against peptidases. A method for synthesizing such a compound is also described.
REFERENCES:
patent: 4206199 (1980-06-01), Fujino et al.
patent: 4251631 (1981-02-01), Simon
patent: 4423034 (1983-12-01), Nakagawa et al.
patent: 4462941 (1984-07-01), Lee et al.
patent: 4859604 (1989-08-01), Gould et al.
patent: 5493007 (1996-02-01), Burnier et al.
patent: 5580853 (1996-12-01), Sytkowski
patent: 5612034 (1997-03-01), Pouletty et al.
patent: 5654276 (1997-08-01), Barrett et al.
patent: 5837247 (1998-11-01), Oppenhelm et al.
patent: 5840733 (1998-11-01), Krantz et al.
patent: 5843440 (1998-12-01), Pouletty et al.
patent: 5874408 (1999-02-01), Nayar
patent: 5877151 (1999-03-01), Pereira
patent: 5942620 (1999-08-01), Krantz et al.
patent: 6087375 (2000-07-01), Bridon et al.
patent: 6103233 (2000-08-01), Pouletty et al.
patent: 6107489 (2000-08-01), Krantz et al.
patent: 6197813 (2001-03-01), Hegenauer
patent: 6277583 (2001-08-01), Krantz et al.
patent: 6277863 (2001-08-01), Krantz et al.
patent: 6329336 (2001-12-01), Bridon et al.
patent: 6403324 (2002-06-01), Krantz et al.
patent: 6437092 (2002-08-01), Ezrin et al.
patent: 6440417 (2002-08-01), Thibaudeau et al.
patent: 6500918 (2002-12-01), Ezrin et al.
patent: 6514500 (2003-02-01), Bridon et al.
patent: 6593295 (2003-07-01), Bridon et al.
patent: 6602981 (2003-08-01), Ezrin et al.
patent: 6610825 (2003-08-01), Ezrin et al.
patent: 6706892 (2004-03-01), Ezrin et al.
patent: 6849714 (2005-02-01), Bridon et al.
patent: 2002/0018751 (2002-02-01), Bridon et al.
patent: 2003/0073630 (2003-04-01), Bridon et al.
patent: 2003/0105867 (2003-06-01), Colrain et al.
patent: 2003/0108568 (2003-06-01), Bridon et al.
patent: 2003/0170250 (2003-09-01), Ezrin et al.
patent: 2004/0127398 (2004-07-01), Bridon et al.
patent: 2004/0138100 (2004-07-01), Bridon et al.
patent: 2004/0156859 (2004-08-01), Ezrin et al.
patent: 2004/0248782 (2004-12-01), Bridon et al.
patent: 2004/0266673 (2004-12-01), Bakis et al.
patent: 2005/0037974 (2005-02-01), Krantz et al.
patent: 2005/0065075 (2005-03-01), Erickson et al.
patent: 2005/0070475 (2005-03-01), Bridon et al.
patent: 252539 (1987-12-01), None
patent: 19936780 (2001-02-01), None
patent: 0602290 (1994-06-01), None
patent: WO-93/25217 (1993-12-01), None
patent: WO-95/00534 (1995-01-01), None
patent: WO-95/10302 (1995-04-01), None
patent: WO-96/06626 (1996-03-01), None
patent: WO-96/28544 (1996-09-01), None
patent: WO-99/24075 (1999-05-01), None
patent: WO-99/24462 (1999-05-01), None
patent: WO-99/48536 (1999-09-01), None
patent: WO 00/69900 (2000-11-01), None
patent: WO-00/76550 (2000-12-01), None
patent: WO-00/76551 (2000-12-01), None
Gunnes et al., “Haemodynamic effects of pharmacological doses of secretin in patients with impaired left ventricular function”, European Heart Journal 7: 146-149 (1986).□□.
Paige et al., “Prolonged circulation of recombinant human granulocyte-colony stimulating factor by covalent linkage to albumin through a heterobifunctional polyethylene glycol”, Pharmaceutical Research 12(12): 1883-1888 (1995).
U.S. Appl. No. 09/424,571, Ezrin et al.
U.S. Appl. No. 09/530,891, Blanchard et al.
U.S. Appl. No. 09/623,533, filed Sep. 5, 2000, Boudjellab et al.
U.S. Appl. No. 09/623,543, filed Sep. 5, 2000, Beliveau et al.
U.S. Appl. No. 09/657,336, filed Sep. 7, 2000, Boudjellab et al.
U.S. Appl. No. 09/657,431, filed Sep. 7, 2000, Beliveau et al.
U.S. Appl. No. 11/040,810, filed Jan. 21, 2005, Bakis et al.
U.S. Appl. No. 11/067,556, filed Feb. 25, 2005, Bidon et al.
Breton, J. et al. (Aug. 1995) “Prolonged Half-life in the Circulation of a Chemical Conjugate Between a Pro-urokinase Derivative and Human Serum Albumin,”Eur. J. Biochem.231(3):563-9.
“Trimethylaminuria (Fish-Malodor Syndrome) and the Flavin Monooxygenases,”Biothech Report, Abstract, 1994/1995 pp. 106-107.
Thim, Lars et al. (1998) “Molecules in Focus: CART, a new Anorectic Peptide,”Int. J. Biochem. Cell. Biol.30:1281-1284.
Endocrinology, 1982, 110(3):1049-1051.
Kapas, Supriya et al. (Oct. 27, 1995) “Cloning and Expression of cDNA Encoding a Rat Adrenomedullin Receptor,”Journal of Biological Chemistry, 270(4):25344-25347.
Smith, Francine et al. (1989) “Atrial Natriuretic Factor During Fetal and Postnatal Life: A Review,”J. Dev. Physiol.,12:55-62.
Stehle, Gerd et al. (1997) “The Loading Rate Determines Tumor Targeting Properties of Methotrexate-Albumin Conjugates in Rats,”Anti-Cancer Drugs, 8:677-685.
Oren, Ziv et al. (1998) “Mode of Action of Linear Amphipathic α-Helical Antimicrobial Peptides,”Biopolymers(Peptide Science), 47:451-463.
Akil, Huda et al. (1984) “Endogenous Opioids: Biology and Function,”Ann. Rev. Neurosci.,7:223-255.
Hirai, Yuko et al. (1979) “A New Mast Cell Degranulating Peptide ‘Mastoparan’ in the Venom of Vespula Lewisii,”Chem. Pharm. Bull., 27(8):1942-1944.
Mumby, Susanne et al. (Jan. 1986) “Antisera of Designed Specificity for Subunits of Guanine Nucleotide-Binding Regulatory Proteins,”Proc. Natl. Acad. Sci.83:265-269.
Otteson, Kenneth M. (1983) “Comparisons of Peptide Sequences with Deprotection Problems in Fmoc Solid Phase Peptide Synthesis,”Proceedings of the 8thAmerican Peptide Symposium, pp. 409-412.
Selkoe, Dennis J. “Physiological Production of the β-Amyloid Protein and the Mechanism of Alzheimer's Disease,”TINS, 16(10):403-409.
Ito, K. et al. (Dec. 1995) “Preparation of Specific Antiserum of Secretin and its Use in Time-Resolved Fluoroimmunoassay,” Journal of the Pharmaceutical Society of Japan, abstract.
Singer, M. V. et al. (1981) “Effect of Adding Albumin to Solutions of Secretin on Pancreatic Volume and Bicarbonate Response,” Scandinavian Journal of Gastroenterology, abstract.
Davis et al, 1991, in Peptide and Protein Drug Delivery, V.H.L. Lee (ed.), Chap. 21, Marcel Dekker, Inc., pp. 831-864.
Poznansky MJ. “Enzyme-protein conjugates: new possibilities for enzyme therapy.” Pharmacol Ther. 1983;21(1):53-76.
Poznansky et al. “Growth hormone-albumin conjugates. Reduced renal toxicity and altered plasma clearance.” FEBS Lett. Oct. 24, 1988;239(1):18-22.
Bridon Dominique P.
Ezrin Alan M.
Holmes Darren L.
Milner Peter G.
Thibaudeau Karen
ConjuChem Biotechnologies Inc.
Desai Anand
Jones Day
Wax Robert A.
LandOfFree
Protection of endogenous therapeutic peptides from peptidase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protection of endogenous therapeutic peptides from peptidase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protection of endogenous therapeutic peptides from peptidase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3899353